JP6041489B2 - 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 - Google Patents

乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 Download PDF

Info

Publication number
JP6041489B2
JP6041489B2 JP2011537663A JP2011537663A JP6041489B2 JP 6041489 B2 JP6041489 B2 JP 6041489B2 JP 2011537663 A JP2011537663 A JP 2011537663A JP 2011537663 A JP2011537663 A JP 2011537663A JP 6041489 B2 JP6041489 B2 JP 6041489B2
Authority
JP
Japan
Prior art keywords
vegf
antibody
subject
administered
cyclophosphamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011537663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509889A (ja
JP2012509889A5 (OSRAM
Inventor
グウェンドリン ファイフ，
グウェンドリン ファイフ，
シー チュン ファン，
シー チュン ファン，
シーアン シュウ，
シーアン シュウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42154236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6041489(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2012509889A publication Critical patent/JP2012509889A/ja
Publication of JP2012509889A5 publication Critical patent/JP2012509889A5/ja
Application granted granted Critical
Publication of JP6041489B2 publication Critical patent/JP6041489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2011537663A 2008-11-22 2009-11-20 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 Active JP6041489B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11710208P 2008-11-22 2008-11-22
US61/117,102 2008-11-22
US17800909P 2009-05-13 2009-05-13
US61/178,009 2009-05-13
US17930709P 2009-05-18 2009-05-18
US61/179,307 2009-05-18
PCT/US2009/065381 WO2010059969A2 (en) 2008-11-22 2009-11-20 Anti-angiogenesis therapy for the treatment of breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016163087A Division JP6850562B2 (ja) 2008-11-22 2016-08-23 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用

Publications (3)

Publication Number Publication Date
JP2012509889A JP2012509889A (ja) 2012-04-26
JP2012509889A5 JP2012509889A5 (OSRAM) 2013-01-24
JP6041489B2 true JP6041489B2 (ja) 2016-12-07

Family

ID=42154236

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011537663A Active JP6041489B2 (ja) 2008-11-22 2009-11-20 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
JP2016163087A Active JP6850562B2 (ja) 2008-11-22 2016-08-23 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
JP2018080848A Withdrawn JP2018138583A (ja) 2008-11-22 2018-04-19 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
JP2020076277A Pending JP2020128389A (ja) 2008-11-22 2020-04-22 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016163087A Active JP6850562B2 (ja) 2008-11-22 2016-08-23 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
JP2018080848A Withdrawn JP2018138583A (ja) 2008-11-22 2018-04-19 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
JP2020076277A Pending JP2020128389A (ja) 2008-11-22 2020-04-22 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用

Country Status (28)

Country Link
US (5) US20100143351A1 (OSRAM)
EP (3) EP3178478A1 (OSRAM)
JP (4) JP6041489B2 (OSRAM)
KR (3) KR20170015525A (OSRAM)
CN (2) CN102223897B (OSRAM)
AR (1) AR074203A1 (OSRAM)
AU (1) AU2009316409A1 (OSRAM)
BR (1) BRPI0916138A2 (OSRAM)
CA (1) CA2744158A1 (OSRAM)
CL (1) CL2011001186A1 (OSRAM)
CY (1) CY1118549T1 (OSRAM)
DK (2) DK2752189T3 (OSRAM)
ES (2) ES2611337T3 (OSRAM)
HR (1) HRP20170059T1 (OSRAM)
HU (2) HUE032693T2 (OSRAM)
IL (2) IL212998A (OSRAM)
LT (1) LT2752189T (OSRAM)
MX (2) MX2011005383A (OSRAM)
PH (1) PH12014502507A1 (OSRAM)
PL (2) PL2361085T5 (OSRAM)
PT (1) PT2752189T (OSRAM)
RU (1) RU2531948C2 (OSRAM)
SG (1) SG171780A1 (OSRAM)
SI (2) SI2752189T1 (OSRAM)
SM (1) SMT201700173T1 (OSRAM)
TW (2) TWI612971B (OSRAM)
WO (1) WO2010059969A2 (OSRAM)
ZA (1) ZA201103321B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846628B2 (en) 2008-05-15 2014-09-30 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
KR20170015525A (ko) * 2008-11-22 2017-02-08 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
AU2011221229B2 (en) 2010-02-23 2015-06-18 F. Hoffmann-La Roche Ag Anti-angiogenesis therapy for the treatment of ovarian cancer
DK4403228T3 (da) * 2011-10-14 2025-10-13 Hoffmann La Roche Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab
BR112014010417A2 (pt) 2011-11-01 2014-11-18 Celgene Corp Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
MX365139B (es) 2012-03-13 2019-05-24 Hoffmann La Roche Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino.
HUE047186T2 (hu) 2013-08-26 2020-04-28 Novartis Ag Új alkalmazás
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
EA201691872A1 (ru) * 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2950936A1 (en) * 2014-07-03 2016-01-07 Imclone Llc Combination therapy of olaratumab, cardioprotective agent and doxorubicin for the treatment of soft tissue sarcoma
CA2955048C (en) 2014-07-14 2020-11-03 University Of Utah Research Foundation In situ solidifying compositions and methods of making and using therof
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR20230144110A (ko) 2017-03-02 2023-10-13 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
WO2019084548A1 (en) * 2017-10-27 2019-05-02 University Of Utah Research Foundation COMPLEX LIQUID IN SITU SOLIDIFICATION COASTALITIES FOR LOCAL ADMINISTRATION OF ANTI-ANGIOGENIC AGENTS OR CHEMOTHERAPEUTIC AGENTS
EP3743120A4 (en) 2018-01-26 2021-10-13 Fluidx Medical Technology, LLC DEVICE AND METHOD FOR USING COMPLEX COACERVATES THAT CONSOLIDATE IN SITU FOR VASCULAR CLOSURE
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
EP3762428A4 (en) * 2018-03-09 2021-12-01 The Regents of the University of California POLYTHERAPY FOR CHEMOR-RESISTANT CANCERS
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111710425A (zh) * 2020-06-19 2020-09-25 复旦大学附属中山医院 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
EP4653019A1 (en) * 2023-01-19 2025-11-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her2 antibody-drug conjugate for treating breast cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
CA2455365C (en) 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
BRPI0513200A (pt) 2004-07-16 2008-04-29 Pfizer Prod Inc uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AU2005269716B2 (en) 2004-07-20 2011-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2582656T3 (es) * 2006-12-19 2016-09-14 Genentech, Inc. Antagonistas específicos del VEGF para terapia adyuvante y neoadyuvante, y el tratamiento de tumores en fase temprana
TW200838875A (en) * 2007-02-01 2008-10-01 Genentech Inc Combination therapy with angiogenesis inhibitors
KR20170015525A (ko) * 2008-11-22 2017-02-08 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
WO2020176087A1 (en) 2019-02-27 2020-09-03 Google Llc Grayscale histogram generation

Also Published As

Publication number Publication date
CN102223897B (zh) 2015-09-23
US20150246124A1 (en) 2015-09-03
HK1213177A1 (zh) 2016-06-30
JP2012509889A (ja) 2012-04-26
WO2010059969A8 (en) 2011-02-03
WO2010059969A2 (en) 2010-05-27
EP2361085A2 (en) 2011-08-31
DK2752189T3 (en) 2017-01-16
AR074203A1 (es) 2010-12-29
CA2744158A1 (en) 2010-05-27
TW201609140A (zh) 2016-03-16
WO2010059969A3 (en) 2010-08-05
MX2011005383A (es) 2011-06-06
RU2531948C2 (ru) 2014-10-27
HUE032693T2 (en) 2017-10-30
MX340724B (es) 2016-07-22
TWI612971B (zh) 2018-02-01
HRP20170059T1 (hr) 2017-03-10
JP2018138583A (ja) 2018-09-06
IL243741A0 (en) 2016-04-21
IL212998A (en) 2016-02-29
PH12014502507A1 (en) 2016-01-18
SMT201700173T1 (it) 2017-05-08
ES2535404T3 (es) 2015-05-11
AU2009316409A1 (en) 2010-05-27
EP2361085B1 (en) 2015-02-25
DK2361085T4 (en) 2018-10-08
CN105214086A (zh) 2016-01-06
KR20180117734A (ko) 2018-10-29
TWI542359B (zh) 2016-07-21
PL2752189T3 (pl) 2017-04-28
ES2611337T3 (es) 2017-05-08
SI2361085T1 (sl) 2015-06-30
JP2017031160A (ja) 2017-02-09
PL2361085T5 (pl) 2018-12-31
KR20170015525A (ko) 2017-02-08
SG171780A1 (en) 2011-07-28
ZA201103321B (en) 2012-08-29
BRPI0916138A2 (pt) 2015-11-17
PL2361085T3 (pl) 2015-08-31
US20100143351A1 (en) 2010-06-10
RU2011125518A (ru) 2012-12-27
EP2361085B9 (en) 2019-01-02
EP2361085B2 (en) 2018-07-18
KR20110086863A (ko) 2011-08-01
JP6850562B2 (ja) 2021-03-31
EP3178478A1 (en) 2017-06-14
IL212998A0 (en) 2011-07-31
CY1118549T1 (el) 2017-07-12
US20210093715A1 (en) 2021-04-01
PT2752189T (pt) 2017-02-02
SI2752189T1 (sl) 2017-02-28
CN105214086B (zh) 2019-09-27
DK2361085T3 (en) 2015-03-09
HUE024872T2 (en) 2016-02-29
ES2535404T5 (es) 2018-11-19
EP2752189B1 (en) 2016-10-26
CL2011001186A1 (es) 2012-02-24
US20170100478A1 (en) 2017-04-13
TW201023887A (en) 2010-07-01
JP2020128389A (ja) 2020-08-27
CN102223897A (zh) 2011-10-19
SI2361085T2 (sl) 2018-11-30
EP2752189A1 (en) 2014-07-09
US20160243227A1 (en) 2016-08-25
KR101807319B1 (ko) 2017-12-11
LT2752189T (lt) 2017-02-10

Similar Documents

Publication Publication Date Title
JP6041489B2 (ja) 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
JP2012524083A (ja) アジュバント癌治療
US20200148756A1 (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
JP2016117718A (ja) 以前に治療された乳癌の治療のための抗血管新生療法
US20220195027A1 (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
AU2017200300A1 (en) Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
HK1213177B (zh) 抗-vegf抗体与化学治疗联合用於治疗乳腺癌的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150507

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20150507

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20150526

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150701

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20150707

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150904

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20150908

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20160209

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20160412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20160524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160823

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20160913

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20161011

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20161011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161108

R150 Certificate of patent or registration of utility model

Ref document number: 6041489

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250